Please Wait...

HA // Hyaluronic Acid

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Hyaluronic acid (HA) is also known as hyaluronate or hyaluronan. This macromolecule is a ubiquitous linear polymer, especially abundant in connective tissues. HA is synthetized in the plasma membrane by a membrane-bound protein by addition of sugar units (D-glucuronic acid and D-N-acetylglucosamine, linked via alternating β-1,4 and β-1,3 glycosidic bonds) from a nucleotide precursor and followed by translocation to the extracellular space (Fraser et al., 1997). HA found in low concentration in blood comes from the peripheral tissues through the lymph and in physiological condition is rapidly took up and degraded by the liver. In patients with liver diseases, such as liver cirrhosis, increased serum levels of HA have been found. Increased blood levels can also be the result of inflammatory condition such as rheumatoid arthritis, psoriasis and scleroderma (Laurent and Fraser, 1992).

Bioclinica Lab employs a sandwich protein binding manual assay, which use Hyaluronic Acid Binding Protein for the capture and detection of HA. This assay is designed for the measurement of Collagen IV in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @bioclinica: @CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of #MobileTechnologies in #CV…
bioclinica (5 minutes ago)
@CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of… https://t.co/0Oc3z6zkO8
bioclinica (10 minutes ago)
RT @CDISC: Special thanks to CDISC Member @bioclinica for hosting CDISC Public Training in Audubon, PA 2-6 Apr 2018. Register today. https:…
bioclinica (26 minutes ago)
Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil… https://t.co/77NOME2Dj7
bioclinica (Yesterday)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace… https://t.co/f9vtRpsbMW
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c… https://t.co/PAdROjo7tE
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen